BigBear Pharmaceutical announced that Selinexor, Venetoclax and Sotorasib were approved in Laos

Vientiane, Laos - Jun 08, 2023 - Big Bear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative treatments for cancer, announced today that three products has been approved by the Lao Ministry of Health.

Approved drugs are:

Selinexor: sold under the brand name SALLYDX, for the treatment of multiple myeloma in adults. It is used in combination with low-dose dexamethasone for the treatment of refractory relapsed multiple myeloid (RRMM). It may also be used in adults to treat certain types of diffuse large B-cell lymphoma.

Venetoclax: sold under the brand name VECLADX, for patients with treated chronic lymphocytic leukemia and refractory or relapsed deletion of 17p mutation gene. It is the first selective inhibitor targeting B-cell lymphoma factor 2 (BCL-2).

Sotorasib: sold under the brand name SOTOLDX, for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying a KRAS G12C mutation who have received at least one prior systemic therapy.

About Big Bear Pharma

Big Bear Pharma is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for cancer. The company has a diverse pipeline of anti-cancer targeted drugs that address various molecular pathways and mechanisms of action. Big Bear Pharma aims to improve the lives of patients with cancer by providing them with more options, better outcomes and lower costs. 

Forward-Looking Statements

To the extent applicable laws and regulations, expressions such as "plan," "target," "expect," "forecast," and similar expressions appearing in this press release are forward-looking statements. The forward-looking statements set forth herein involve a number of risks and uncertainties that may differ materially from actual results. Important factors leading to such differences include, but are not limited to, changes in regulations and/or economic conditions, uncertainty in clinical research results, exposure to various market risks, and other factors beyond the control of the company.